TrialEuropean journal of neurology2022

Efficacy and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis with suboptimal response to prior disease-modifying therapies: A primary analysis from the phase 3b CASTING single-arm, open-label trial.

Patrick Vermersch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.